You're always banging on about how the Stable Disease count to Progressive Disease count did not reach the goal set at the beginning of the canine b-cell lymphoma 2B trial.
But that was irrelevant by the end of the trial, because the trial revealed that the extension in the canine life was little affected by whether that measure, which was the whole point of this "bench mark". What's wrong with your memory that you cannot remember this crucial detail?
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1143
-
- There are more pages in this discussion • 282 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |